Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 1 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 4 |
Forrest at al. (procyclic) | no | yes: 4 |
Silverman et al. | no | yes: 2 |
Pissara et al. | yes | yes: 22 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 4 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 8 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 18 |
NetGPI | no | yes: 0, no: 18 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005853 | eukaryotic translation elongation factor 1 complex | 2 | 19 |
GO:0032991 | protein-containing complex | 1 | 19 |
GO:0005829 | cytosol | 2 | 2 |
GO:0110165 | cellular anatomical entity | 1 | 2 |
GO:0005737 | cytoplasm | 2 | 1 |
Related structures:
AlphaFold database: A4HAJ1
Term | Name | Level | Count |
---|---|---|---|
GO:0006414 | translational elongation | 5 | 2 |
GO:0008152 | metabolic process | 1 | 2 |
GO:0009058 | biosynthetic process | 2 | 2 |
GO:0009059 | macromolecule biosynthetic process | 4 | 2 |
GO:0009987 | cellular process | 1 | 2 |
GO:0034645 | obsolete cellular macromolecule biosynthetic process | 4 | 2 |
GO:0043170 | macromolecule metabolic process | 3 | 2 |
GO:0044237 | cellular metabolic process | 2 | 2 |
GO:0044249 | cellular biosynthetic process | 3 | 2 |
GO:0044260 | obsolete cellular macromolecule metabolic process | 3 | 2 |
GO:0071704 | organic substance metabolic process | 2 | 2 |
GO:1901576 | organic substance biosynthetic process | 3 | 2 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003676 | nucleic acid binding | 3 | 19 |
GO:0003746 | translation elongation factor activity | 4 | 19 |
GO:0005488 | binding | 1 | 19 |
GO:0008135 | translation factor activity, RNA binding | 3 | 19 |
GO:0045182 | translation regulator activity | 1 | 19 |
GO:0090079 | translation regulator activity, nucleic acid binding | 2 | 19 |
GO:0097159 | organic cyclic compound binding | 2 | 19 |
GO:1901363 | heterocyclic compound binding | 2 | 19 |
GO:0005085 | guanyl-nucleotide exchange factor activity | 3 | 2 |
GO:0030234 | enzyme regulator activity | 2 | 2 |
GO:0030695 | GTPase regulator activity | 4 | 2 |
GO:0060589 | nucleoside-triphosphatase regulator activity | 3 | 2 |
GO:0098772 | molecular function regulator activity | 1 | 2 |
GO:0140677 | molecular function activator activity | 2 | 2 |
GO:0140678 | molecular function inhibitor activity | 2 | 2 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 27 | 29 | PF00675 | 0.552 |
CLV_PCSK_KEX2_1 | 103 | 105 | PF00082 | 0.476 |
CLV_PCSK_PC1ET2_1 | 103 | 105 | PF00082 | 0.476 |
CLV_PCSK_SKI1_1 | 103 | 107 | PF00082 | 0.631 |
CLV_PCSK_SKI1_1 | 111 | 115 | PF00082 | 0.555 |
CLV_PCSK_SKI1_1 | 15 | 19 | PF00082 | 0.520 |
DEG_Nend_Nbox_1 | 1 | 3 | PF02207 | 0.447 |
DOC_CYCLIN_yCln2_LP_2 | 42 | 48 | PF00134 | 0.671 |
DOC_MAPK_gen_1 | 166 | 174 | PF00069 | 0.364 |
DOC_MAPK_MEF2A_6 | 36 | 44 | PF00069 | 0.659 |
DOC_PP2B_LxvP_1 | 42 | 45 | PF13499 | 0.667 |
DOC_USP7_MATH_1 | 119 | 123 | PF00917 | 0.446 |
DOC_USP7_UBL2_3 | 106 | 110 | PF12436 | 0.608 |
DOC_USP7_UBL2_3 | 111 | 115 | PF12436 | 0.573 |
LIG_APCC_ABBA_1 | 86 | 91 | PF00400 | 0.615 |
LIG_BRCT_BRCA1_1 | 121 | 125 | PF00533 | 0.380 |
LIG_Clathr_ClatBox_1 | 171 | 175 | PF01394 | 0.364 |
LIG_FHA_1 | 131 | 137 | PF00498 | 0.353 |
LIG_FHA_2 | 20 | 26 | PF00498 | 0.532 |
LIG_FHA_2 | 90 | 96 | PF00498 | 0.614 |
LIG_NRBOX | 1 | 7 | PF00104 | 0.465 |
LIG_SH2_STAT5 | 23 | 26 | PF00017 | 0.618 |
LIG_SUMO_SIM_anti_2 | 197 | 202 | PF11976 | 0.236 |
LIG_SUMO_SIM_par_1 | 131 | 137 | PF11976 | 0.369 |
LIG_SUMO_SIM_par_1 | 170 | 177 | PF11976 | 0.364 |
LIG_TRAF2_1 | 92 | 95 | PF00917 | 0.561 |
LIG_UBA3_1 | 123 | 128 | PF00899 | 0.443 |
MOD_CK2_1 | 19 | 25 | PF00069 | 0.521 |
MOD_CK2_1 | 89 | 95 | PF00069 | 0.635 |
MOD_GlcNHglycan | 179 | 182 | PF01048 | 0.380 |
MOD_Plk_1 | 130 | 136 | PF00069 | 0.373 |
MOD_Plk_2-3 | 194 | 200 | PF00069 | 0.380 |
MOD_Plk_4 | 119 | 125 | PF00069 | 0.364 |
MOD_Plk_4 | 9 | 15 | PF00069 | 0.657 |
MOD_SUMO_rev_2 | 107 | 113 | PF00179 | 0.515 |
MOD_SUMO_rev_2 | 121 | 129 | PF00179 | 0.335 |
MOD_SUMO_rev_2 | 149 | 159 | PF00179 | 0.378 |
MOD_SUMO_rev_2 | 175 | 180 | PF00179 | 0.364 |
MOD_SUMO_rev_2 | 25 | 30 | PF00179 | 0.566 |
MOD_SUMO_rev_2 | 95 | 105 | PF00179 | 0.650 |
TRG_DiLeu_BaEn_4 | 95 | 101 | PF01217 | 0.615 |
TRG_NLS_MonoExtC_3 | 110 | 115 | PF00514 | 0.629 |
TRG_NLS_MonoExtN_4 | 110 | 115 | PF00514 | 0.680 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N0P4W7 | Leptomonas seymouri | 61% | 99% |
A0A0N1HZF7 | Leptomonas seymouri | 74% | 87% |
A0A0S4JK70 | Bodo saltans | 63% | 84% |
A0A1X0PA37 | Trypanosomatidae | 67% | 90% |
A0A3Q8IVV7 | Leishmania donovani | 64% | 98% |
A0A3S5H7W1 | Leishmania donovani | 81% | 86% |
A0A422N8N9 | Trypanosoma rangeli | 68% | 90% |
A4HAJ3 | Leishmania braziliensis | 90% | 67% |
A4HAJ7 | Leishmania braziliensis | 100% | 86% |
A4HP03 | Leishmania braziliensis | 66% | 99% |
A4I9P1 | Leishmania infantum | 81% | 86% |
A4IDB2 | Leishmania infantum | 64% | 98% |
A5D989 | Bos taurus | 43% | 74% |
D0A2X9 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 55% | 100% |
E9ASR3 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 60% | 99% |
E9B4Q3 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 79% | 84% |
O74173 | Schizosaccharomyces pombe (strain 972 / ATCC 24843) | 43% | 96% |
O96827 | Drosophila melanogaster | 38% | 93% |
P12262 | Artemia salina | 50% | 100% |
P29522 | Bombyx mori | 38% | 93% |
P29692 | Homo sapiens | 46% | 73% |
P30151 | Xenopus laevis | 53% | 91% |
P34460 | Caenorhabditis elegans | 37% | 97% |
P34827 | Trypanosoma cruzi | 64% | 93% |
P57776 | Mus musculus | 46% | 73% |
Q4Q3C1 | Leishmania major | 81% | 100% |
Q4R3D4 | Macaca fascicularis | 46% | 73% |
Q66NE2 | Leishmania major | 61% | 98% |
Q68FR9 | Rattus norvegicus | 47% | 73% |
Q69BZ7 | Penicillium citrinum | 35% | 90% |